

Research Article

Lifestyle Factors and the Risk of a Second Breast Cancer
after Ductal Carcinoma *In Situ*Vicki Hart McLaughlin¹, Amy Trentham-Dietz^{2,3}, John M. Hampton², Polly A. Newcomb^{2,4}, and
Brian L. Sprague¹

Abstract

Background: Little information exists on lifestyle factors that affect prognosis after treatment for ductal carcinoma *in situ* (DCIS) breast cancer. Improved understanding of the role of lifestyle factors is important to survivors wishing to reduce their risk of a second breast cancer diagnosis.

Methods: We examined the association between body mass index (BMI), physical activity, and alcohol intake, and risk of a second breast cancer diagnosis among 1,925 DCIS survivors in the Wisconsin In Situ Cohort. Exposures were self-reported during biennial patient interviews. Second breast cancer diagnoses were validated via pathology report. Cox proportional hazards regression was used to estimate the association between prediagnosis, postdiagnosis, and change in exposure levels and the risk of a second diagnosis, with adjustment for patient, tumor, and treatment factors.

Results: Over a mean of 6.7 years of follow-up, 162 second breast cancer diagnoses were reported, including 57 invasive events, 60 *in situ* events, and 45 diagnoses of unknown stage. A significant trend of increasing risk of a second diagnosis was found over increasing categories of postdiagnosis alcohol intake ($P_{\text{trend}} = 0.02$). Among premenopausal women, increased prediagnosis BMI was associated with a reduced risk of a second diagnosis (HR = 0.93; 95% confidence interval, 0.88–0.99).

Conclusion: DCIS survivors may reduce their risk of a second diagnosis by reducing postdiagnosis alcohol consumption.

Impact: The population of DCIS survivors is projected to surpass one million by the year 2016. Our results suggest that these women may be able to reduce their risk of a second diagnosis through moderation of alcohol consumption. *Cancer Epidemiol Biomarkers Prev*; 23(3); 450–60. ©2014 AACR.

Introduction

Ductal carcinoma *in situ* (DCIS) is a noninvasive breast cancer characterized by the development of malignant cells that are confined to the basement membrane of the breast duct (1). The incidence of DCIS has increased steadily since the 1980s (2), mirroring the rise in screening mammography (3). Although overall survival after treatment for DCIS is high (5-year disease-specific survival rates approach 100%; ref. 2), the risk of developing invasive breast cancer is 4-fold higher for women with a DCIS diagnosis compared with the general population (4).

Given the large numbers of DCIS survivors and the increased risk of subsequent breast cancer diagnoses in

this population, research specific to the prevention of second events is needed. A number of tumor factors have been identified that are associated with an increased likelihood of a second breast cancer diagnosis, including nuclear grade, larger tumor size, and detection by palpation rather than mammography (5). However, little information exists on lifestyle factors that may affect prognosis after a DCIS diagnosis and may be useful to DCIS survivors wishing to reduce their risk of a second event.

Elevated body mass index (BMI), physical activity, and alcohol consumption have been established as risk factors for both primary invasive and DCIS breast cancer (6–11). Studies have also examined these factors in relation to recurrence after an invasive breast cancer diagnosis, with suggestive but inconclusive results (12–20). There is very little evidence about the impact of these lifestyle factors on the risk of a second breast cancer diagnosis after DCIS. A single study of BMI and second breast cancer diagnoses in a DCIS population reported a 2-fold increase in risk for those who were obese at diagnosis compared with those who were normal weight (21). To our knowledge, no studies have assessed postdiagnosis BMI, physical activity, or alcohol intake and the risk of second breast cancer events in an exclusively DCIS population.

Authors' Affiliations: ¹Department of Surgery and Office of Health Promotion Research, University of Vermont, Burlington, Vermont; ²University of Wisconsin Carbone Cancer Center; ³Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin; and ⁴Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington

Corresponding Author: Vicki Hart McLaughlin, 1 South Prospect Street, Room 4428D, Burlington, VT 05401. Phone: 802-656-8756; Fax: 802-656-8826; E-mail: victoria.mclaughlin@uvm.edu

doi: 10.1158/1055-9965.EPI-13-0899

©2014 American Association for Cancer Research.

We examined the association of BMI, physical activity, and alcohol intake with the risk of a second *in situ* or invasive breast cancer diagnosis in a large, population-based cohort of DCIS survivors. Measurements of exposure at prediagnosis, postdiagnosis, and the change from pre- to postdiagnosis were considered.

Materials and Methods

Study population

Details of the Wisconsin In Situ Cohort (WISC) have been described previously (22). Briefly, the cohort enrolled women with a first primary diagnosis of noninvasive breast cancer reported to the mandatory Wisconsin Cancer Reporting System during 1997–2006. The current study population includes 1,925 women with a first primary DCIS diagnosis, and is composed of 838 incident DCIS cases recruited for a case-control study during 1997–2001 (23, 24) and 1,087 additional cases recruited during 2002–2006. All participants in the cohort were female residents of Wisconsin, ages 20 to 74 years at diagnosis. Eligibility was limited to cases with a known date of diagnosis, a listed telephone number, and the ability to conduct a telephone interview. All subjects provided verbal informed consent and the study was approved by the University of Wisconsin Health Sciences Institutional Review Board (Madison, WI).

Data collection

All participants completed a baseline telephone interview at enrollment into the study (median of 1.3 years after diagnosis). Follow-up interviews were conducted biennially starting in 2003 and are on-going. Interviews were conducted by telephone until 2010, at which point a mailed survey was utilized. The current study uses data collected through 2010 and includes a baseline and up to three follow-up interviews (Fig. 1). A woman was eligible for recontact if at least 2 years had passed since her last interview. Because enrollment and recontact periods

overlapped, not all women were eligible for each cycle of recontact interviews. Of the women eligible for a first recontact interview, 79% participated; of those who were eligible for a second recontact interview, 85% participated; and of those who were eligible for a third recontact (mailed survey), 73% participated.

Breast cancer second events. During each interview, women were asked to self-report new breast cancer diagnoses. In years that women were not contacted, a questionnaire was mailed to each subject for reporting new diagnoses. For the purposes of these analyses, a second event was defined as any second breast cancer diagnosis (invasive or *in situ*), and includes ipsilateral events, contralateral events, and events of unknown laterality. Pathology reports were requested to confirm the self-reported diagnoses. Of the 126 self-reported diagnoses for which pathology information could be gathered, 117 were verified and nine were refuted (93% accuracy). Pathology reports were unavailable for an additional 45 self-reported diagnoses as a result of patient or facility refusal to disclose records, and were included as second events in these analyses.

Behavioral characteristics. All exposure information was assessed via self-report during telephone interviews (1997–2006) or mailed survey (2010). During the baseline interview, subjects were asked to report their current weight, their weight at one-year prediagnosis, and their height. Current weight was subsequently reported at each recontact interview or survey. BMI at each data collection period was then calculated from the self-reported weights and height.

Information was gathered at baseline on regular participation in recreational physical activity at one-year prediagnosis using a questionnaire patterned after the Nurses' Health Study that had been previously validated (25). Physical activity categories included: jogging, running, bicycling, racquet sports, aerobics/dance, swimming, walking/hiking, and other strenuous activity.




Figure 1. Study timeline and participation rates: WISC 1997–2010.

Subjects reported the hours per week spent on the activity and the number of months per year in which the activity was performed. Recreational physical activity was updated at each subsequent interview, with subjects reporting their regular participation in strenuous exercises or sports over the past year in an open-ended question. This assessment of physical activity during follow-up has demonstrated an association between physical activity and breast cancer risk in previous analysis within the WISC cohort (26). In all assessments, activities performed for at least 30 minutes per week for at least 3 months of the year were considered regular. A variable was created for each data collection period to reflect the average total hours per week spent on regular recreational physical activity.

Subjects reported the number of bottles or cans of beer, glasses of wine, and drinks of hard liquor consumed per day, week, or month at one-year prediagnosis at the baseline interview. The same information was gathered during subsequent interviews in reference to typical alcohol consumed over the past year. This information was used to create a variable representing the total drinks consumed per week for each data collection period.

Information on reproductive and menstrual histories, past and current exogenous hormone use, medication use, medical and family history, mammographic screening history, method of tumor detection (screening mammography or symptomatic), and demographics was obtained during the baseline and follow-up interviews or survey. Tumor characteristics for the initial DCIS diagnosis were obtained from the Wisconsin Cancer Registry, which receives mandatory cancer diagnosis reports from physicians, hospitals, and clinics across Wisconsin. Tumor characteristics included date of diagnosis, histology, laterality, grade, and tumor size. The registry also provided treatment information for the initial DCIS breast cancer, including treatment type and date of treatment.

Statistical analysis

Descriptive characteristics of the study population were examined overall and by outcome status. Missing values for all covariates and for exposures at each data collection period were estimated using multiple imputation with ten imputations (27). The imputation model included all covariates listed in Table 1 in addition to mammographic screening history, age at first birth, age at menarche, and history of breast biopsy and benign breast disease, all assessed at the baseline interview. Regression analyses used the combined results of the ten imputations to create valid statistical inferences that account for the uncertainty created by the missing values (28, 29). Where variables with imputed values were categorized for presentation, classification of subjects into categories was based on the mode (categorical) or mean (continuous) of the ten estimated values for each subject created under the imputation model.

Cox proportional hazards regression was used to estimate the crude and multivariable-adjusted HRs for the

associations between the exposures and outcomes. Follow-up time for each subject was defined as the time from initial DCIS diagnosis to the date of a second breast cancer diagnosis or date of last contact or death. The multivariable models were adjusted for the following confounding factors that were selected *a priori* based on previous literature (15, 16), (18, 19), (30, 31) and included: age at diagnosis, menopausal status, method of detection, surgical treatment type, radiation therapy, tamoxifen use, year of diagnosis, tumor size, and tumor grade. Each exposure was additionally adjusted for the remaining two exposures (e.g., the analysis for BMI was adjusted for physical activity and alcohol intake). The postdiagnosis analyses were further adjusted for prediagnosis values of the exposures.

To make use of the postdiagnosis measurement of each exposure at each data collection period, repeated measures were incorporated in the Cox proportional hazard model in the postdiagnosis analyses. BMI, physical activity, and alcohol intake were treated as time-dependent variables and updated with the most relevant values during the analysis (32). Entry into the postdiagnosis model was at the time of the first interview assessing postdiagnosis exposures (baseline interview for the evaluation of BMI and first recontact interview for the evaluation of physical activity and alcohol intake). Second breast cancer diagnoses that occurred before the entry time were excluded from each analysis.

Change in exposure was calculated as the difference in exposure level between prediagnosis and each postdiagnosis data collection period. Annualized rates of change were established by dividing the change in exposure by the time interval of the change in years to account for differences in the spacing of patient interviews and surveys. The annualized rates of change were included in the multivariable models as time-dependent variables and updated with the relevant values during the analysis. Categories for the annualized rate of change were chosen to reflect a change of approximately 1 kg/m² for BMI, 1 hour/week for physical activity, and 0.5 drinks/week for alcohol intake over the mean follow-up period. Models for change in exposure were additionally adjusted for time since diagnosis.

Effect modification was evaluated by entering cross-product terms in the multivariable model using the time-dependent exposure variables. Menopausal status, postmenopausal hormone use, type of surgical treatment for original DCIS, and tamoxifen use were tested in each model as potential effect modifiers. Interactions were considered significant at the $P \leq 0.05$ level. Where significant interaction was observed, results were stratified by levels of the effect modifier and presented separately.

Forty-five of the 162 second breast cancer events included in these analyses were not confirmed via pathology report as a result of patient or facility refusal to disclose records. A sensitivity analysis was performed excluding these 45 self-reported diagnoses to assess the robustness of our results. Because second diagnoses of invasive breast

Table 1. Prediagnosis subject characteristics and distribution of second breast cancer diagnoses; *N* (%): WISC DCIS cohort, 1997–2010

	Total <i>N</i> = 1,925	Second breast cancer diagnosis <i>N</i> = 162	No second breast cancer diagnosis <i>N</i> = 1,763	<i>P</i> ^a
Age at diagnosis, y	—	—	—	0.13
20–44	238 (12.4)	21 (13.0)	217 (12.3)	—
45–54	684 (35.5)	66 (40.7)	618 (35.1)	—
55–64	585 (30.4)	36 (22.2)	549 (31.1)	—
65–74	418 (21.7)	39 (24.1)	379 (21.5)	—
Menopausal status	—	—	—	0.01
Premenopausal	617 (32.1)	70 (43.2)	547 (31.0)	—
Postmenopausal	1,147 (59.6)	82 (50.6)	1,065 (60.4)	—
Unknown	161 (8.4)	10 (6.2)	151 (8.6)	—
First degree family history of breast cancer	—	—	0.85	—
No	1,380 (71.7)	114 (70.4)	1,266 (71.8)	—
Yes	430 (22.3)	39 (24.1)	391 (22.2)	—
Unknown	115 (6.0)	9 (5.6)	106 (6.0)	—
Postmenopausal hormone use	—	—	—	<0.01
Never	1,287 (66.9)	129 (79.6)	1,158 (65.7)	—
Ever	587 (30.5)	30 (18.5)	557 (31.6)	—
Unknown	51 (2.7)	3 (1.9)	48 (2.7)	—
Parity	—	—	—	0.55
No births	270 (14.0)	27 (16.7)	243 (13.8)	—
One birth	197 (10.2)	13 (8.0)	184 (10.4)	—
Two births	594 (30.9)	53 (32.7)	541 (30.7)	—
3+ births	839 (43.6)	67 (41.4)	772 (43.8)	—
Unknown	25 (1.3)	2 (1.2)	23 (1.3)	—
Education	—	—	—	0.37
< High school diploma	93 (4.8)	5 (3.1)	88 (5.0)	—
High school diploma	736 (38.2)	64 (39.5)	672 (38.1)	—
Some college	514 (26.7)	47 (29.0)	467 (26.5)	—
College degree	552 (28.7)	46 (28.4)	506 (28.7)	—
Unknown	30 (1.6)	0	30 (1.7)	—
Smoking status	—	—	—	0.38
Never	1,053 (54.7)	88 (54.3)	965 (54.7)	—
Former	557 (28.9)	54 (33.3)	503 (28.5)	—
Current	288 (15.0)	20 (12.4)	268 (15.2)	—
Unknown	27 (1.4)	0	27 (1.5)	—
Surgical treatment	—	—	—	<0.01
Ipsilateral mastectomy	593 (30.8)	41 (25.3)	552 (31.3)	—
Bilateral mastectomy	81 (4.2)	0	81 (4.6)	—
BCS without radiation	176 (9.1)	28 (17.3)	148 (8.4)	—
BCS with radiation	826 (42.9)	74 (45.7)	752 (42.7)	—
Biopsy only	49 (2.6)	7 (4.3)	42 (2.4)	—
Unknown	200 (10.4)	12 (7.4)	188 (10.7)	—
Tamoxifen use (excluding after recurrence)	—	—	—	0.02
No	1,039 (54.0)	105 (64.8)	934 (53.0)	—
Yes	638 (33.1)	44 (27.2)	594 (33.7)	—
Unknown	248 (12.9)	13 (8.0)	235 (13.3)	—
Mode of detection	—	—	—	0.41
Mammography	1,595 (82.9)	129 (79.6)	1,466 (83.2)	—
Symptomatic	266 (13.8)	28 (17.3)	238 (13.5)	—
Unknown	64 (3.3)	5 (3.1)	59 (3.3)	—

^a*P* for χ^2 test comparing women with and without a second breast cancer diagnosis among those with known covariate status.

cancer are of particular importance, exploratory analyses were performed using only invasive second events as the outcome variable using the same multivariable models and methods described above.

All statistical analysis was performed using SAS statistical software Version 9.2 (SAS Institute Inc.).

Results

Over an average of 6.7 years of follow-up (range 0.4–15.3 years), 162 second breast cancer events were observed. Of the 117 second events that could be confirmed via pathology report, 57 (49%) were invasive diagnoses and 60 (51%) were *in situ* diagnoses. Characteristics of the study population are provided in Table 1. Women with any second breast cancer diagnosis were more likely to be premenopausal and to have never taken hormone therapy. These women were also more likely to have elected breast conserving surgery (BCS) as opposed to mastectomy as surgical treatment and were less likely to have used tamoxifen following their original diagnosis (Table 1).

BMI was not associated with the risk of any second breast cancer event in the full cohort [prediagnosis HR = 0.99; 95% confidence interval (CI), 0.96–1.02; postdiagnosis HR = 1.03; 95% CI, 0.97–1.10 per 1 kg/m²; Table 2]. However, the relation between both pre- and postdiag-

nosis BMI and risk of a second breast cancer diagnosis were significantly modified by menopausal status ($P_{\text{interaction}} < 0.01$). In premenopausal women, a statistically significant decrease in risk was observed with increasing prediagnosis BMI (HR = 0.93; 95% CI, 0.88–0.99), and premenopausal women who were obese at prediagnosis were at significantly reduced risk compared with normal weight counterparts (HR = 0.23; 95% CI 0.07–0.71; Table 2). A similar inverse association was observed between premenopausal BMI and risk of an invasive second breast cancer diagnosis (HR = 0.87; 95% CI, 0.74–0.99). There was no association between postdiagnosis BMI and risk of any second event or an invasive second event among premenopausal women. In postmenopausal women, no association was observed between pre- or postdiagnosis BMI and risk of any second breast cancer diagnosis (prediagnosis HR = 1.03; 95% CI, 0.99–1.06; postdiagnosis HR = 1.03; 95% CI, 0.94–1.12); and these results did not change when examining invasive second events only (Table 2). The association between BMI and a second breast cancer event was not modified by postmenopausal hormone use, tamoxifen use, or type of treatment.

Pre- and postdiagnosis levels of physical activity were not significantly associated with risk of any second breast cancer diagnosis in the full cohort (prediagnosis

Table 2. HRs and 95% CIs for the association between BMI and the risk of a second breast cancer diagnosis: WISC DCIS cohort, 1997–2010

Second diagnosis	All second breast cancer diagnoses					Invasive second breast cancer diagnoses						
	HR (95% CI) ^a	P_{trend}^c	Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b		HR (95% CI) ^a	P_{trend}^c	Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b	
			HR (95% CI) ^a	P_{trend}^c	HR (95% CI) ^a	P_{trend}^c			HR (95% CI) ^a	P_{trend}^c	HR (95% CI) ^a	P_{trend}^c
All women (kg/m ²)												
<25.0	78	1.00 (Ref.)	0.27	1.00 (Ref.)	0.21	26	1.00 (Ref.)	0.75	1.00 (Ref.)	0.64		
25–29.9	56	1.10 (0.77–1.58)	—	1.03 (0.60–1.44)	—	22	1.29 (0.71–2.35)	—	0.71 (0.32–1.55)	—		
30+	28	0.83 (0.53–1.30)	—	1.15 (0.52–2.13)	—	9	0.82 (0.38–1.81)	—	1.34 (0.44–4.07)	—		
Continuous per 1 kg/m ²	162	0.99 (0.96–1.02)	—	1.03 (0.97–1.10)	—	57	0.99 (0.94–1.04)	—	1.00 (0.90–1.11)	—		
Premenopausal women (kg/m ²)												
<25.0	50	1.00 (Ref.)	0.19	1.00 (Ref.)	0.44	18	1.00 (Ref.)	0.04	1.00 (Ref.)	0.43		
25–29.9	20	0.83 (0.48–1.43)	—	1.17 (0.54–2.11)	—	5	0.53 (0.18–1.49)	—	0.40 (0.11–1.45)	—		
30+	4	0.23 (0.07–0.71)	—	1.14 (0.33–3.92)	—	1	0.16 (0.02–1.28)	—	0.50 (0.05–5.42)	—		
Continuous per 1 kg/m ²	74	0.93 (0.88–0.99)	—	1.04 (0.95–1.13)	—	24	0.87 (0.74–0.99)	—	0.95 (0.82–1.13)	—		
Postmenopausal women (kg/m ²)												
<25.0	28	1.00 (Ref.)	0.37	1.00 (Ref.)	0.22	8	1.00 (Ref.)	0.89	1.00 (Ref.)	0.22		
25–29.9	36	1.53 (0.91–2.57)	—	1.04 (0.50–1.79)	—	17	1.93 (0.75–4.13)	—	1.26 (0.41–3.88)	—		
30+	24	1.50 (0.84–2.66)	—	1.21 (0.42–2.45)	—	8	1.17 (0.63–4.95)	—	2.39 (0.57–10.1)	—		
Continuous per 1 kg/m ²	88	1.03 (0.99–1.06)	—	1.03 (0.94–1.12)	—	33	1.03 (0.97–1.10)	—	1.03 (0.90–1.18)	—		

^aAdjusted for age at diagnosis, menopausal status, mode of detection, treatment type, postmenopausal hormone use, tamoxifen use, year of diagnosis, tumor size, tumor grade, and remaining lifestyle factors.

^bPostdiagnosis results are additionally adjusted for prediagnosis levels of each lifestyle factor.

^c P is for linear trend across categories of each lifestyle factor.

Table 3 HRs and 95% CIs for the association between physical activity and the risk of a second breast cancer diagnosis: WISC DCIS cohort, 1997–2010

	All second breast cancer diagnoses					Invasive second breast cancer diagnoses				
	Second diagnosis	Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b		Second diagnosis	Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b	
		HR (95% CI) ^a	<i>P</i> _{trend} ^c	HR (95% CI) ^a	<i>P</i> _{trend} ^c		HR (95% CI) ^a	<i>P</i> _{trend} ^c	HR (95% CI) ^a	<i>P</i> _{trend} ^c
Total physical activity (h/wk)										
No activity	44	1.00 (Ref.)	0.66	1.00 (Ref.)	0.90	17	1.00 (Ref.)	0.15	1.00 (Ref.)	0.08
>0–2	37	0.97 (0.62–1.52)	–	0.37 (0.12–1.07)	–	15	1.02 (0.50–2.08)	–	1.05 (0.20–5.58)	–
>2–5	54	1.16 (0.77–1.75)	–	0.92 (0.47–1.81)	–	17	0.93 (0.47–1.86)	–	1.75 (0.55–5.81)	–
5+	27	0.81 (0.49–1.33)	–	0.89 (0.36–2.22)	–	8	0.60 (0.25–1.43)	–	1.78 (0.41–7.61)	–
Continuous per 1 h/wk	162	0.98 (0.94–1.02)	–	0.97 (0.88–1.08)	–	57	0.98 (0.91–1.05)	–	1.03 (0.90–1.17)	–
BCS with or without radiation (h/wk)										
No activity	27	1.00 (Ref.)	0.54	1.00 (Ref.)	0.58	11	1.00 (Ref.)	0.14	1.00 (Ref.)	0.24
>0–2	27	1.07 (0.62–1.84)	–	0.31 (0.07–1.40)	–	10	0.95 (0.39–2.32)	–	1.98 (0.27–14.0)	–
>2–5	36	1.17 (0.70–1.96)	–	1.41 (0.61–3.22)	–	11	0.95 (0.39–2.27)	–	3.91 (0.82–19.5)	–
5+	17	0.76 (0.40–1.42)	–	1.24 (0.39–3.92)	–	6	0.70 (0.25–2.00)	–	2.78 (0.37–22.0)	–
Continuous per 1 h/wk	107	0.97 (0.92–1.02)	–	0.99 (0.88–1.12)	–	38	1.00 (0.92–1.08)	–	1.05 (0.90–1.28)	–
Ipsilateral mastectomy (h/wk)										
No activity	15	1.00 (Ref.)	0.18	1.00 (Ref.)	0.07	6	^d	–	^d	–
>0–2	10	1.03 (0.45–2.35)	–	0.40 (0.07–2.23)	–	5	–	–	–	–
>2–5	12	0.84 (0.37–1.88)	–	0.13 (0.01–1.57)	–	3	–	–	–	–
5+	8	0.72 (0.30–1.75)	–	0.06 (0.00–1.51)	–	1	–	–	–	–
Continuous per 1 h/wk	45	0.97 (0.88–1.06)	–	0.67 (0.45–1.02)	–	15	–	–	–	–

^aAdjusted for age at diagnosis, mode of detection, treatment type, postmenopausal hormone use, tamoxifen use, year of diagnosis, tumor size, tumor grade, and remaining lifestyle factors.

^bPostdiagnosis results are additionally adjusted for prediagnosis levels of each lifestyle factor.

^c*P* is for linear trend across categories.

^dLow numbers of invasive second breast cancer diagnoses among women treated with ipsilateral mastectomy precluded separate analysis of this subgroup.

HR = 0.98; 95% CI, 0.94–1.02; postdiagnosis HR = 0.97; 95% CI, 0.88–1.08), and these results were similar when considering only invasive second events (Table 3). A significant interaction was observed between the physical activity and the type of treatment for the original DCIS in the postdiagnosis analysis ($P_{\text{interaction}} = 0.01$). A trend suggested that women treated with ipsilateral mastectomy had a reduced risk of any second breast cancer diagnosis with every additional hour per week of postdiagnosis physical activity (HR = 0.67; 95% CI, 0.45–1.02; $P_{\text{trend}} = 0.07$; Table 3). In contrast, no association between postdiagnosis physical activity and risk of any second breast cancer diagnosis was observed for women treated with BCS with or without radiation (HR = 0.99; 95% CI, 0.88–1.12). The low number of invasive second events among women treated with ipsilateral mastectomy precluded stratified analysis of postdiagnosis physical activity in this subgroup (Table 3). Likewise, small numbers of women treated with bilateral mastectomy and biopsy prohibited separate analysis of these treatment types. No significant interaction was observed between physical

activity and menopausal status, postmenopausal hormone use, or tamoxifen use.

Although the risk estimates for individual categories of alcohol intake did not reach statistical significance, a significant linear trend of increasing risk of any second breast cancer diagnosis was observed over the categories of increasing postdiagnosis alcohol intake ($P = 0.02$). When measured continuously, increases in risk of any second breast cancer diagnosis with increasing alcohol intake were not statistically significant in either the pre- or postdiagnosis analysis (prediagnosis HR = 1.02; 95% CI, 0.99–1.05; postdiagnosis HR = 1.03; 95% CI, 0.94–1.11; Table 4). When considering only invasive second breast cancer diagnoses, risk estimates increased with increasing postdiagnosis alcohol intake, but the linear trend was no longer significant ($P = 0.15$; Table 4). No significant interaction was observed between alcohol intake and menopausal status, treatment type, postmenopausal hormone use, or tamoxifen use.

No association was observed between the pre- to postdiagnosis change in BMI (HR = 0.98; 95% CI, 0.84–1.15 for

Table 4. HRs and 95% CIs for the association between alcohol consumption and the risk of a second breast cancer diagnosis: WISC DCIS cohort, 1997–2010

	Second diagnosis	All second breast cancer diagnoses				Invasive second breast cancer diagnoses				
		Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b		Prediagnosis (N = 1,925)		Postdiagnosis (N = 1,903) ^b		
		HR (95% CI) ^a	P _{trend} ^c	HR (95% CI) ^a	P _{trend} ^c	HR (95% CI) ^a	P _{trend} ^c	HR (95% CI) ^a	P _{trend} ^c	
Total alcohol (drinks/wk)										
No alcohol	27	1.00 (Ref.)	0.88	1.00 (Ref.)	0.02	9	1.00 (Ref.)	0.18	1.00 (Ref.)	0.15
>0–<2	80	0.98 (0.62–1.53)	–	1.28 (0.59–2.78)	–	25	0.95 (0.43–2.08)	–	1.38 (0.37–5.47)	–
2–<7	35	0.91 (0.54–1.53)	–	1.76 (0.64–4.80)	–	15	1.23 (0.52–2.90)	–	1.40 (0.14–4.35)	–
7+	20	1.04 (0.58–1.88)	–	2.59 (0.61–11.0)	–	8	1.21 (0.45–3.22)	–	1.74 (0.17–9.68)	–
Continuous per 1 drink/wk	162	1.02 (0.99–1.05)	–	1.03 (0.94–1.11)	–	57	1.04 (0.99–1.09)	–	1.05 (0.90–1.23)	–

^aAdjusted for age at diagnosis, menopausal status, mode of detection, postmenopausal hormone use, tamoxifen use, year of diagnosis, tumor size, tumor grade, remaining lifestyle factors, and prediagnosis levels of each lifestyle factor.

^bPostdiagnosis results are additionally adjusted for prediagnosis levels of each lifestyle factor.

^cP is for linear trend across categories.

1 kg/m² per year change), physical activity (HR = 0.93; 95% CI, 0.73–1.20 for 1 hour/week per year change), or alcohol intake (HR = 1.01; 0.70–1.46 for 1 drink/week per year change) and risk of any second breast cancer diagnosis or invasive second breast cancer diagnosis (Table 5). No significant interactions were observed between change in any exposure and menopausal status, treatment type, postmenopausal hormone use, or tamoxifen use.

Sensitivity analysis using only those second events that could be confirmed via pathology report (N = 117) resulted in wider confidence intervals; however, the risk estimates remained stable for all of the exposure–outcome relationships (data not shown).

Discussion

In this large, population-based cohort of DCIS survivors, we observed a significant trend of increasing risk of a second breast cancer diagnosis over categories of increasing postdiagnosis alcohol intake. We also found a decrease in the risk of a second breast cancer diagnosis with increasing prediagnosis BMI in premenopausal women. No significant associations were observed between BMI in postmenopausal women or physical activity and the overall risk of a second breast cancer diagnosis in this cohort. Similar patterns in risk were observed in analyses limited to invasive second breast cancer diagnoses.

Our observed trend of increasing risk of a second breast cancer diagnosis over the categories of increasing postdiagnosis alcohol intake is consistent with previous studies of this association in survivors of invasive breast cancer. In a study of women diagnosed with early-stage invasive breast cancer, Kwan and colleagues found a 35% increase in risk of local, distant, or new primary breast cancer for those consuming six or more grams of alcohol per day (approximately 3–4 drinks per week) at

1 to 2 years postdiagnosis compared with those consuming fewer than 0.5 g per day (19). Similarly, Holm and colleagues found a 65% increase in the risk of any second breast cancer event following an invasive diagnosis for women consuming 20 or more grams of alcohol per day (approximately 10 drinks per week) postdiagnosis compared with those consuming less than 10 g per day, excluding nondrinkers (18). Recently, Newcomb and colleagues found that moderate alcohol consumption before diagnosis was associated with improved breast cancer survival after an invasive diagnosis, although there was no association between postdiagnosis alcohol consumption and breast cancer survival (33). It is possible that alcohol consumption may increase the risk of second breast cancer incidence, but may not substantially increase the likelihood of aggressive second diagnoses that result in death, particularly among DCIS survivors, who have very high survival rates with current treatments.

Few studies have investigated body mass and the risk of second breast cancer diagnosis in premenopausal women. In the only study to our knowledge examining BMI and second events in an exclusively DCIS population, Habel and colleagues found a 2-fold increase in risk for women in the highest decile of BMI at diagnosis (>30.8 kg/m²) compared with the lowest decile (<22.0 kg/m²; ref. 21). Their study included both pre- and postmenopausal women and noted that risk estimates were similar when stratified by menopausal status, although separate results were not shown. Analyses of BMI and recurrence after invasive breast cancer in premenopausal women have shown an increase in risk (34) or no association (12, 13) with elevated prediagnosis BMI. In contrast, we observed a reduction in overall risk of any second breast cancer diagnosis and risk of an invasive second breast cancer diagnosis with increasing prediagnosis BMI in

Table 5. HRs and 95% CIs for pre- to postdiagnosis change in lifestyle factors and the risk of a second breast cancer diagnosis: WISC DCIS cohort, 1997–2010

	All second breast cancer diagnoses			Invasive second breast cancer diagnoses		
	Second diagnosis	HR (95% CI) ^b	P _{trend} ^c	Second diagnosis	HR (95% CI) ^b	P _{trend} ^c
Change in BMI ^{a,d}						
Decrease > 0.13 kg/m ² per year	33	0.95 (0.55–1.63)	0.61	13	1.06 (0.43–2.65)	0.33
Stable within ± 0.13 kg/m ² per year	36	1.00 (Ref.)	—	12	1.00 (Ref.)	—
Increase > 0.13 kg/m ² per year	71	0.88 (0.55–1.41)	—	27	1.00 (0.44–2.26)	—
Continuous for 1 kg/m ² per year change	140	0.98 (0.84–1.15)	—	52	0.93 (0.71–1.21)	—
Change in total physical activity ^{a,d}						
Decrease > 0.13 h/wk per year	19	0.95 (0.48–1.88)	0.45	6	1.00 (0.30–3.46)	0.33
Stable within ± 0.13 h/wk per year	24	1.00 (Ref.)	—	7	1.00 (Ref.)	—
Increase > 0.13 h/wk per year	11	0.74 (0.35–1.57)	—	5	1.04 (0.30–3.67)	—
Continuous for 1 h/wk change	54	0.93 (0.73–1.20)	—	18	1.02 (0.61–1.68)	—
Change in total alcohol ^{a,d}						
Decrease > 0.064 drinks/wk per year	7	0.73 (0.32–1.66)	0.13	3	0.62 (0.15–2.72)	0.13
Stable within ± 0.064 drinks/wk per year	30	1.00 (Ref.)	—	8	1.00 (Ref.)	—
Increase > 0.064 drinks/wk per year	17	1.58 (0.81–3.06)	—	7	1.79 (0.61–5.47)	—
Continuous for 1 drink/wk per year change	54	1.01 (0.70–1.46)	—	18	1.23 (0.67–2.16)	—

^aCategories for BMI, physical activity, and alcohol intake represent the annualized change from prediagnosis to most recent postdiagnosis level (or last contact before a second breast diagnosis).

^bAdjusted for age at diagnosis, menopausal status, mode of detection, treatment type, postmenopausal hormone use, tamoxifen use, year of diagnosis, tumor size, tumor grade, physical activity, alcohol use, time since diagnosis, remaining lifestyle factors, and prediagnosis levels of each lifestyle factor.

^cP is for linear trend across categories of each change in lifestyle factor.

^dCategories reflect a change of approximately 1 kg/m² for BMI, 1 h/wk for physical activity, and 0.5 drinks/wk for alcohol intake over the median follow-up period.

premenopausal women. Two factors may contribute to the differences in these results. First, our study included both ipsilateral and contralateral second events as endpoints. Therefore, new primary breast cancers may have been included as second events, and there is evidence that elevated BMI is protective against primary breast cancer in premenopausal women (35). Some previous studies, including Habel and colleagues, restricted second events to those in the ipsilateral breast or metastasis. Secondary analysis of our data in premenopausal women with ipsilateral second events still indicated a reduction in risk with increasing prediagnosis BMI, but was limited in power by the small number of confirmed ipsilateral events. Second, previous studies conducted in survivors of invasive breast cancer involved women who had been treated with chemotherapy. It has been suggested that underdosing of chemotherapy may occur in obese women because of concern for toxicity (35). Underdosing may have contributed to an increase in the risk of recurrence in obese women in previous studies. Chemotherapy is not recommended for the treatment of DCIS (1, 36).

In postmenopausal women, the risk estimates indicated an elevated risk of a second breast cancer diagnosis with increasing categories of pre- and postdiagnosis BMI,

although these results were not statistically significant. In a population of pre- and postmenopausal breast cancer survivors, Chen and colleagues observed a significant increase in the risk of an ipsilateral second event or metastasis for women who were obese at 6 months postdiagnosis compared with those who were normal weight (HR = 1.49; 95% CI, 1.08–2.06 for BMI > 30 kg/m²; ref. 31). Using a definition of second breast cancer events similar to ours, Inkampe and colleagues found a 43% increased risk for women who were obese versus nonobese at enrollment (pre- and postmenopausal combined; ref. 30). Our findings are consistent with these previous studies, and the lack of significant association in our analysis may be a result of limited statistical power after stratifying by menopausal status.

Previous studies of second breast cancers after invasive disease have reported a reduction in risk with increased levels of physical activity (17, 37) or no association (15, 16). Although we did not observe an association between physical activity and risk of any second breast cancer diagnosis in the full cohort, we found suggestive trend for reduction in risk with increasing postdiagnosis physical activity among women treated with ipsilateral mastectomy. A similar reduction in risk was not observed

among women treated with BCS, with or without radiation. Previous studies examining recurrence after invasive breast cancer have not stratified results by type of treatment for the original breast cancer, although most controlled for chemotherapy and radiation therapy in their analyses. Because the majority of second events among women treated with ipsilateral mastectomy were in the contralateral breast, it may be that physical activity reduces the risk of new primary cancers as opposed to being associated with the previously diagnosed DCIS. Stratified analysis of ipsilateral and contralateral second breast cancer events among women treated with ipsilateral mastectomy in our cohort was precluded by small numbers of second breast cancer events. Likewise, stratified analysis examining only invasive second breast cancer diagnoses was limited by the small number of second events in each subgroup.

BMI, physical activity, and alcohol consumption all may affect levels of circulating sex hormones that could impact a woman's risk of a second breast cancer diagnosis. A positive association has been found between BMI and levels of circulating estrogen as a result of the conversion of androstenedione to estrogen in adipose tissue (38, 39). Alcohol consumption has also been shown to be directly related to elevated endogenous estrogen levels in both pre- and postmenopausal women (19). Another possible mechanism linking lifestyle factors to second breast cancer diagnoses may be related to insulin and insulin-like growth factors, which promote the development of sex steroid hormones and may elevate cell proliferation (40). Both weight loss and regular physical activity may reduce insulin levels (41). The effect of insulin on survival after breast cancer has been shown to be independent of BMI (42), suggesting that physical activity may be an effective means of risk reduction even for women of healthy weight.

The results of our study must be interpreted in the context of the limitations. All of our exposures were self-reported. Substudies conducted in the study cohort found good reliability for body weight and alcohol consumption (intraclass correlation coefficient > 0.75; ref. 22); however, the possibility exists for misclassification. This is particularly true for the assessment of prediagnosis behaviors because these were reported at a median of 1.3 years after diagnosis and may have been affected by the knowledge of the DCIS diagnosis. Second breast cancer events occurring before the baseline interview were excluded from the prediagnosis analyses and second events occurring before the first postdiagnosis interview were excluded from postdiagnosis analyses, meaning that it is unlikely that any misclassification differs by the knowledge of a second breast cancer diagnosis. Although participation rates in the WISC cohort are high (Fig. 1), nonresponse at each data collection period may have the potential to affect our results. Women with a second breast cancer diagnosis may have been more likely to drop out of the study because of additional treatment burden, and this would limit our ability to detect an association between the

lifestyle exposures and the risk of a second breast cancer event. A comparison of women who participated in at least one recontact interview to nonparticipating women did not reveal significant differences in prediagnosis BMI, physical activity, or alcohol consumption (data not shown).

Invasive second events are of particular importance for women with DCIS. With a relatively small number of invasive second events, we had limited power to detect statistically significant associations, although similar patterns in the associations were observed for the risk of any second event and the risk of invasive second events. Laterality of the second breast cancer diagnosis must also be considered in the interpretation of our results. Second events in the contralateral breast may reflect new primary breast cancers as opposed to an association with the original DCIS. Our definition is consistent with much of the previous literature investigating BMI, physical activity, alcohol intake and second breast cancer events, but may have limited our ability to specifically understand DCIS as a marker of propensity to develop a second breast cancer diagnosis. Separate analyses of second events by laterality were limited to exploratory investigations. As data collection continues in this study population, further analyses of specific outcomes are planned. Finally, data on estrogen receptor (ER) and progesterone receptor (PR) status were largely unavailable in our study, although the majority of DCIS seem to be ER positive (43). The mechanisms relating BMI, physical activity, and alcohol intake to breast cancer development are thought to involve sex hormone production, which suggests that the effects could be modified by ER and PR status. Further research is required to understand whether our results are modified by these prognostic features.

This is the first study to our knowledge to assess physical activity, alcohol intake, and postdiagnosis BMI in relation to risk of second breast cancer diagnoses in an exclusively DCIS population, and the second to explore prediagnosis BMI and second breast cancer diagnoses. Strengths of our study include the large, population-based cohort of DCIS survivors with extensive follow-up. In addition, we were able to control for tumor characteristics such as size, grade, and method of detection in our analysis, all of which have been previously associated with the risk of a second event after noninvasive breast cancer (5). Our prospective study design allowed us to take advantage of multiple exposure measurements to reflect changes in exposure with time since the original DCIS diagnosis.

Diagnoses of DCIS continue to rise with the widespread use of screening mammography and the population of DCIS survivors is projected to surpass 1 million by the year 2016 (44). Our findings about BMI, physical activity, and alcohol consumption may suggest ways for women with DCIS to reduce their risk of a second breast cancer diagnosis. Future studies are needed to establish the consistency of our results. Such studies would benefit from the use of objective measures of BMI and physical

activity, the incorporation of biomarkers to evaluate mechanistic pathways, and the evaluation of variation in risk estimates by hormone receptor status of the original DCIS diagnosis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: V. Hart McLaughlin, A. Trentham-Dietz, B.L. Sprague

Development of methodology: V. Hart McLaughlin, A. Trentham-Dietz, J.M. Hampton, P.A. Newcomb

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Trentham-Dietz, J.M. Hampton, P.A. Newcomb

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V. Hart McLaughlin, A. Trentham-Dietz, J.M. Hampton, B.L. Sprague

Writing, review, and/or revision of the manuscript: V. Hart McLaughlin, A. Trentham-Dietz, J.M. Hampton, P.A. Newcomb, B.L. Sprague
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Hart McLaughlin, J.M. Hampton
Study supervision: A. Trentham-Dietz, B.L. Sprague

Grant Support

This work was supported by the National Cancer Institute (U54 CA163303 to B. L. Sprague, R01 CA067264 to A. Trentham-Dietz, R01 CA047147 to P.A. Newcomb, and P30 CA014520 to A. Trentham-Dietz), the Department of Defense Breast Cancer Research Program (W81XWH-11-0214 to A. Trentham-Dietz), and the American Society of Preventive Oncology Fellowship Award sponsored by Susan G. Komen for the Cure and the Prevent Cancer Foundation (PCF-0596 to B.L. Sprague).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 4, 2013; revised November 21, 2013; accepted November 22, 2013; published OnlineFirst January 8, 2014.

References

- Lee RJ, Vallow LA, McLaughlin SA, Tzou KS, Hines SL, Peterson JL. Ductal carcinoma in situ of the breast. *Int J Surg Oncol* 2012; 2012:123549.
- SEER cancer statistics review, 1975–2010 [homepage on the Internet]. Bethesda, MD: National Cancer Institute. Based on November 2012 SEER data submission. Available from: http://seer.cancer.gov/csr/1975_2010/.
- Ernster V, Ballard-Barbash R, Barlow W, Zheng Y, Weaver D, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening. *J Natl Cancer Inst* 2002;94:1546–54.
- Wnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. *Lancet* 2000;355:724–5.
- Shamliyan T, Wang S, Virnig B, Tuttle T, Kane R. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma *in situ*. *Journal of the National Cancer Institute. Monographs* 2010;2010:121–9.
- Suzuki R, Orsini N, Saji S, Key T, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. *Int J Cancer* 2009;124:698–712.
- McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? *Oncologist* 2003;8:326–34.
- Key J, Hodgson S, Omar R, Jensen TK, Thompson SG, Boobis AR, et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *CCC. Cancer Causes Control*. 2006;17:759–70.
- La Vecchia C, Giordano S, Hortobagyi G, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. *Oncologist* 2011;16:726–9.
- Monnikhof E, Elias S, Vleems F, van der Tweel I, Schult AJ, Voskuil DW, et al. Physical activity and breast cancer: A systematic review. *Epidemiology* 2007;18:137–57.
- Coronado G, Beasley J, Livaudais J. Alcohol consumption and the risk of breast cancer. *Salud pública de México* 2011;53:440–7.
- Caan B, Emond J, Natarajan L, Castillo A, Gunderson EP, Habel L, et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. *Breast Cancer Res Treat* 2006;99:47–57.
- Caan B, Kwan M, Hartzell G, Castillo A, Slattery ML, Sternfeld B, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. *Cancer Causes Control* 2008;19:1319–28.
- Kroenke C, Chen W, Rosner B, Holmes M. Weight, weight gain, and survival after breast cancer diagnosis. *J Clin Oncol* 2005;23:1370–8.
- Bertram LAC, Stefanick M, Saquib N, Natarajan L, Patterson RE, Bardwell W, et al. Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: Findings from the WHEL study. *Cancer Causes Control* 2011;22:427–35.
- Sternfeld B, Weltzien E, Quesenberry C, Castillo AL, Kwan M, Slattery ML, et al. Physical activity and risk of recurrence and mortality in breast cancer survivors: Findings from the LACE study. *Cancer Epidemiol, Biomarkers Prev* 2009;18:87–95.
- Holmes M, Chen W, Feskanich D, Kroenke C, Colditz G. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005;293:2479–86.
- Holm M, Olsen A, Christensen J, Kroman NT, Bidstrup PE, Johansen C, et al. Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality - results from a prospective cohort with a wide range of variation in alcohol intake. *Int J Cancer* 2013;132:686–94.
- Kwan M, Kushi L, Weltzien E, Tam EK, Castillo A, Sweeney C, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: The life after cancer epidemiology study. *J Clin Oncol* 2010;28:4410–6.
- Flatt S, Thomson C, Gold E, Natarajan L, Rock CL, Al-Delaimy WK, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. *Cancer Epidemiol Biomarkers Prev* 2010; 19:681–8.
- Habel LA, Daling JR, Newcomb PA, Self SG, Porter PL, Stanford JL, et al. Risk of recurrence after ductal carcinoma *in situ* of the breast. *Cancer Epidemiol Biomarkers Prev* 1998;7:689–96.
- Sprague B, Trentham Dietz A, Nichols H, Hampton J, Newcomb P. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. *Breast Cancer Res Treat* 2010;124:487–95.
- Nichols H, Trentham Dietz A, Egan K, Titus Ernstoff L, Hampton J, Newcomb P. Oral contraceptive use and risk of breast carcinoma *in situ*. *Cancer Epidemiol Biomarkers Prev* 2007;16:2262–8.
- Trentham Dietz A, Nichols H, Egan K, Titus Ernstoff L, Hampton J, Newcomb P. Cigarette smoking and risk of breast carcinoma in situ. *Epidemiology* 2007;18:629–38.
- Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. *Int J Epidemiol* 1994;23:991–9.
- Sprague BL, Trentham-Dietz A, Titus-Ernstoff L, Egan KM, Hampton JM, Newcomb PA. Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:236–43.
- Schafer J. Analysis of incomplete multivariate data. London: Chapman and Hall; 1997.
- Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987.
- Rubin DB. Inference and missing data. *Biometrika* 1976;63:581–92.
- Imkampe A, Bates T. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis. *Breast J* 2010;16:156–61.

31. Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, et al. Obesity and weight change in relation to breast cancer survival. *Breast Cancer Res Treat* 2010;122:823–33.
32. Therneau T. *Modeling survival data: extending the cox model*. New York: Springer-Verlag; 2000.
33. Newcomb PA, Kampman E, Trentham-Dietz A, Egan KM, Titus LJ, Baron JA, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. *J Clin Oncol* 2013;31:1939–46.
34. Loi S, Milne R, Friedlander M, McCredie MR, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1686–91.
35. Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast Cancer Res Treat* 2010;123:627–35.
36. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JA, et al. Standard for the management of ductal carcinoma *in situ* of the breast (DCIS). *CA Cancer J Clin* 2002;52:256–76.
37. Friedenreich C, Gregory J, Kopciuk K, Mackey J, Courneya K. Prospective cohort study of lifetime physical activity and breast cancer survival. *Int J cancer* 2009;124:1954–62.
38. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. *Obstet Gynecol* 1978;130:448–55.
39. McTiernan A, Rajan K, Tworoger S, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. *J Clin Oncol* 2003;21:1961–6.
40. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. *J Natl Cancer Inst* 2000;92:1472–89.
41. McTiernan A, Irwin M, Vongruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. *J Clin Oncol* 2010;28:4074–80.
42. Goodwin P, Ennis M, Pritchard K, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol* 2002;20:42–51.
43. Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, et al. Prognostic significance of oncogenic markers in ductal carcinoma *in situ* of the breast: a clinicopathologic study. *Breast J* 2009;15:120–32.
44. Sprague B, Trentham Dietz A. Prevalence of breast carcinoma *in situ* in the United States. *JAMA* 2009;302:846–8.

Cancer Epidemiology, Biomarkers & Prevention

Lifestyle Factors and the Risk of a Second Breast Cancer after Ductal Carcinoma *In Situ*

Vicki Hart McLaughlin, Amy Trentham-Dietz, John M. Hampton, et al.

Cancer Epidemiol Biomarkers Prev 2014;23:450-460. Published OnlineFirst January 8, 2014.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-13-0899](https://doi.org/10.1158/1055-9965.EPI-13-0899)

Cited articles This article cites 39 articles, 13 of which you can access for free at:
<http://cebp.aacrjournals.org/content/23/3/450.full#ref-list-1>

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/23/3/450.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/23/3/450>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.